Albumin clinical trials
Albumin is named as an intervention in 11 current clinical trials in our India, China, Sweden, Netherlands, Denmark, Austria, Czechia, Mexico and South Korea registers. 8 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Institute of Liver and Biliary Sciences, India (2). The most-studied condition is Acute Kidney Injury.
How Albumin works
All drug targets →- AscitesPhase 3
- SepsisPhase 3
- Acute kidney injuryPhase 3
- Acute lung injuryPhase 3
- Acute respiratory distress syndromePhase 3
- Acute-on-chronic liver failurePhase 3
- Chronic obstructive pulmonary diseasePhase 3
- Dengue diseasePhase 3
- EdemaPhase 3
- Heart failurePhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201451, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Albumin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Albumin
11 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Albumin
19 conditionsAll 19 conditions
| Condition (as registered) | Trials |
|---|---|
| Acute Kidney Injury | 2 |
| Acute Variceal Bleeding | 1 |
| Cirrhosis | 1 |
| Decompensated Liver Cirrhosis | 1 |
| Liver Cirrhosis | 1 |
| Ulcerative Colitis (UC) | 1 |
| Acute Ischemic Stroke | 1 |
| Diabetes | 1 |
| Type 2 Diabetes | 1 |
| Intensive Care Patients | 1 |
| Intensive Care Unit Patients | 1 |
| Critical Illness | 1 |
| Colorectal Cancer | 1 |
| Urologic Cancer | 1 |
| Gynecologic Cancer | 1 |
| Colorectal Disorders | 1 |
| Ischemic Stroke | 1 |
| Urine Output Decreased | 1 |
| Pediatric Cardiac Surgery | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Institute of Liver and Biliary Sciences, India | 2 |
| King George's Medical University | 1 |
| Shanghai East Hospital | 1 |
| Capital Medical University | 1 |
| Lu jin ，MD | 1 |
| Anders Perner | 1 |
| Joachim Zdolsek | 1 |
| University Hospital Hradec Kralove | 1 |
| Jose J Zaragoza, MD MSc | 1 |
| Seoul National University Hospital | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Albumin trials
How many clinical trials are testing Albumin?
11 current trials in our India, China, Sweden, Netherlands, Denmark, Austria, Czechia, Mexico and South Korea registers name Albumin as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Albumin trials recruiting patients?
Yes. 8 of the 11 trials are recruiting: 1 with sites in India, 2 with sites in China, 2 with sites in Sweden, 1 with sites in Netherlands, 1 with sites in Denmark, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Mexico and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Albumin clinical trials?
Institute of Liver and Biliary Sciences, India (2), King George's Medical University (1), Shanghai East Hospital (1) and Capital Medical University (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Albumin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Albumin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Albumin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.